Biotech companies have fared well recently in the IPO market in both the US and the UK. New legislation in the US has eased access to public markets and the AIM market in London continues to be attractive for emerging biotech companies.
If you’re considering an IPO to raise capital for your biotech company, here are the four top tips you need to prep you on how to prepare for your big launch.
1. Intellectual property is key
Wrap up any and all Intellectual Property (IP) issues before kicking off an IPO process. Most advisors and investors are not as IP savvy as you and the key people in your company and will be spooked by the hint of any IP issues.
Wrinkles in IP licenses, outstanding options to acquire rights or potential threats to your IP from third parties are just a few of the issues that need to be bottomed out before the IPO. If not, you should have at least a crystal clear and lay explanation on hand to garner confidence among your advisors, solidify your valuation and most importantly, secure investors.
2. Set the structure
Early on in the process, ensure you line up tax and legal advisors you’re comfortable with and who cover all the global jurisdictions touched by both the IPO and by any share schemes.
It’s critical the tax advisors and legal advisors are aligned on the structure of your IPO framework including:
In what jurisdiction will the listing company be based?
Is a reorganization of the company’s structure required for tax efficiency and (crucially) how long will the legal steps of any such re-organization take?
Having an IPO structure that’s well considered from both a tax and legal perspective and complete (or near complete) in the early stages of an IPO should help avoid expensive and frustrating delays in the process.
3. Get the legal house in order
As in any exit transaction, substantial due diligence will be conducted on your company prior to an IPO. Ensure all your corporate documents and corporate secretarial matters are in order to smooth the process. Key individuals at the company should be available to assist in refining due diligence reviews and answer questions related to due diligence.
4. Keep management onside
Don’t underestimate the amount of work involved in an IPO. This can be hugely time-consuming and is often a new full time job for management, in addition to the work required for the successful operation of the business.
Have a dedicated IPO team within the Company – appoint key contacts for advisors and ensure consistent management participation in advisor meetings. Despite the huge range of characters you’ll have advising you on your IPO, from PR executives to lawyers to bankers, company management is key for driving the process. Regular insight and responsiveness from management ensures that your legal and other advisors can operate at top efficiency.
So, here are the key takeaways to prep for your biotech IPO:
- Be prepared – get the house in order and leave no stone unturned. If you don’t turn it, someone else will!
- Speak to advisers early. Pick the team and ensure you explore all structuring angles early.
- Be financially prepared – an IPO is a costly exercise.
- Have a dedicated internal team and ensure the business can function.